Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
SITC 2024 – Arcus springs a TIGIT surprise
Reports of Arc-10's failure are greatly exaggerated, the company argues.
ESMO 2024 – iTeos TIGIT meets its efficacy criteria
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
